Abbvie pays $ 700 million for the drug to overcome resistance in multiple myeloma

Antibodies that bind to two targets are an established way to treat the multiple myelom of blood cancer. Aiming to garnish these drugs, Abbvie obtained rights on a drug at the start of the clinic that works by linking three targets.

The drug, named ISB 2001, comes from Igi Therapeutics, a subsidiary of Ichnos Glenmark Innovation. Abbvie said Thursday that he paid $ 700 million in advance for rights to this multi-specific commitment to T cells in North America, Europe, Japan and Great China.

In Cell Engage is a type of antibody medication that works by linking a target on an immune cell and another target on a cancer cell, bringing the two together so that the immune cell can kill cancer. IGI adds a third target to this approach as a means of overcoming drug resistance. ISB 2001 is a Trisppecific T cell committed designed to bind to CD3 on T cells, and BCMA and CD38 on several myeloma cells. The two -target binding on multiple myeloma cells improves the binding force to the cancer cell, even when the target protein is expressed at low levels. It is also intended to reduce the side effects outside the target of therapy.

During the annual meeting of the American Society of Clinical ONCology last month, the IGI presented the data of a phase 1 test of the ISB 2001 in patients with highly pre -pruned multiple myeloma. The company indicated that the results of 35 patients have shown that the drug has led to a sustained overall response rate of 79% and to a full / strict full response rate of 30%. The company said that the ISB 2001 security profile was favorable; Cytokine liberation syndrome cases were light and the only case of neurotoxicity which was reported was classified as grade 1.

The trisppecific approach could provide an advantage on bispecific drugs currently available for multiple myeloma. Johnson & Johnson’s stable of multiple myeloma products includes Tecvayli, a bispecific drug that binds to CD3 on T cells and BCMA on cancer cells. Meanwhile, Elrexfio de Pfizer binds to CD38 and BCMA. The most recent bispecific for multiple myeloma is Lynozyfic de Regeneron Pharmaceuticals, a bispecific drug drawing CD3 and BCMA granted FDA approval last week.

“Multispecific, including trisppecific antibodies, represent a new border in immuno-oncology with the potential to provide deeper and more sustainable responses by initiating several objectives simultaneously,” said the Thakkar roopal, an executive vice-president and development, in a prepared declaration.

According to ISB 2001 progress as part of ABBVIE, IGI could receive up to $ 1.225 billion in significant payments, as well as fees for the sale of an approved drug. The drug IGI represents the second multi-specific agreement for Abbvie this year. In January, Abbvie signed a license option for SIM0500, a trisppecific antibody from Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group. SIM0500 is designed to bind to CD3 on T and GPRC5D and BCMA cells on several myeloma cells. This approach could make a competitor for Talvey, an antibody J & J Bispecific which links to CD3 and GPRC5D.

A phase 1 test in the United States and China assesses the Simcere medication in patients with multiple relapse or refractory myeloma. Abbvie’s initial payment in Simcere has not been disclosed. Option fees and step payments could pay payment to more than a billion dollars.

Abbvie photo